Global Ankylosing Spondylitis Market Size & Outlook

The ankylosing spondylitis industry worldwide is expected to reach a projected revenue of US$ 7,910.8 million by 2027. A compound annual growth rate of 8.3% is expected of the worldwide ankylosing spondylitis industry from 2020 to 2027.
Revenue, 2019 (US$M)
$4,194.4
Forecast, 2027 (US$M)
$7,910.8
CAGR, 2020 - 2027
8.3%
Report Coverage
Worldwide

Global ankylosing spondylitis market highlights

  • The global ankylosing spondylitis market generated a revenue of USD 4,194.4 million in 2019 and is expected to reach USD 7,910.8 million by 2027.
  • The market is expected to grow at a CAGR (2020 - 2027) of 8.3% by 2027.
  • In terms of segment, humira accounted for a revenue of USD 1,051.6 million in 2019.
  • Others Drugs is the most lucrative drug segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2019.
  • Country-wise, U.S. is expected to register the highest CAGR from 2020 to 2027.

Global data book summary

Market revenue in 2019USD 4,194.4 million
Market revenue in 2027USD 7,910.8 million
Growth rate8.3% (CAGR from 2019 to 2027)
Largest segmentHumira
Fastest growing segmentOthers Drugs
Historical data covered2016 - 2018
Base year for estimation2019
Forecast period covered2020 - 2027
Quantitative unitsRevenue in USD million
Market segmentationCosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others Drugs

Other key industry trends

  • In terms of revenue, the North America accounted for 60.3% of the global ankylosing spondylitis market in 2019.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2027.
  • By country, U.S. is the fastest growing regional market and is projected to reach USD 3,997.5 million by 2027.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Ankylosing Spondylitis Market Companies

Name Profile # Employees HQ Website

Global ankylosing spondylitis market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ankylosing spondylitis market will help companies and investors design strategic landscapes.


Humira was the largest segment with a revenue share of 25.07% in 2019. Horizon Databook has segmented the Global ankylosing spondylitis market based on cosentyx, humira, simponi, remicade, enbrel, cimzia, others drugs covering the revenue growth of each sub-segment from 2016 to 2027.


  • Global Ankylosing Spondylitis Drug Outlook (Revenue, USD Million, 2016-2027)
    • Cosentyx
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • Others Drugs

Reasons to subscribe to Global ankylosing spondylitis market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global ankylosing spondylitis market databook

  • Our clientele includes a mix of ankylosing spondylitis market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global ankylosing spondylitis market, including forecasts for subscribers. This global databook contains high-level insights into Global ankylosing spondylitis market from 2016 to 2027, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global ankylosing spondylitis market size, by regions, 2016-2027 (US$M)

Top 10 countries: Ankylosing spondylitis market size, 2019 (US$M)

Global ankylosing spondylitis market share, by drug, 2019 & 2027 (%, US$M)

Ankylosing spondylitis market: Opportunity assessment by country

Global ankylosing spondylitis market, by region, 2019 (US$M)

Global ankylosing spondylitis market size, by regions, 2016-2027 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more